Buy EOLS by Oct 9, 2026.

Been looking into Evolus for a while and figured I’d put my thinking out there. The injectable aesthetics space is changing a lot with the newer products being much more subtle than old school Botox, which used to give people that frozen look. That’s pulling in a younger crowd too, not just the usual demographic. Evolus themselves reckon the addressable market is around $19B. Right now it’s basically Galderma and AbbVie (who own Allergan/Botox) running the show, doing something like …